We are live on
!
Find out more
Arrowstreet Capital Portfolio holdings
AUM
$185B
1-Year Est. Return
39.58%
This Fund
S&P 500
This Quarter
Est. Return
+10.23%
1 Year Est. Return
+39.58%
3 Year Est. Return
+145.48%
5 Year Est. Return
+192.07%
10 Year Est. Return
+749.75%
AUM
$43B
AUM Growth
+$121M
(+0.28%)
Cap. Flow
-$3.21B
Cap. Flow
% of AUM
-7.47%
Top 10 Holdings %
Top 10 Hldgs %
18.86%
Holding
2,029
New
505
Increased
717
Reduced
446
Closed
331
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intel
INTC
|
+$285M |
| 2 |
Applied Materials
AMAT
|
+$234M |
| 3 |
Micron Technology
MU
|
+$185M |
| 4 |
Merck
MRK
|
+$161M |
| 5 |
NXP Semiconductors
NXPI
|
+$152M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$505M |
| 2 |
Bank of America
BAC
|
+$339M |
| 3 |
Nike
NKE
|
+$335M |
| 4 |
Union Pacific
UNP
|
+$329M |
| 5 |
Citigroup
C
|
+$277M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.49% |
| 2 | Financials | 16.82% |
| 3 | Consumer Discretionary | 16.55% |
| 4 | Healthcare | 14.39% |
| 5 | Industrials | 8.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Intel
INTC
$466B
| $1.14B | 2.64% |
18,976,061
+5,094,626
| +37% | +$285M |
|
2
Visa
V
$677B
| $1.09B | 2.52% |
5,778,905
-509,814
| -8% | -$91.9M |
|
3
Mastercard
MA
$477B
| $982M | 2.28% |
3,289,067
-678,165
| -17% | -$191M |
|
|
4
Merck
MRK
$324B
| $929M | 2.16% |
10,698,936
+1,959,272
| +22% | +$161M |
|
5
Microsoft
MSFT
$2.84T
| $881M | 2.05% |
5,586,424
-1,330,215
| -19% | -$195M |
|
6
Starbucks
SBUX
$118B
| $863M | 2.01% |
9,812,894
-30,419
| -0.3% | -$2.59M |
|
7
Biogen
BIIB
$29.9B
| $718M | 1.67% |
2,420,191
-242,164
| -9% | -$67.2M |
|
8
Rio Tinto
RIO
$148B
| $632M | 1.47% |
10,643,240
-172,612
| -2% | -$9.36M |
|
9
AbbVie
ABBV
$458B
| $454M | 1.06% |
5,128,458
-2,335,648
| -31% | -$194M |
|
10
AstraZeneca
AZN
$263B
| $430M | 1% |
4,314,320
+20,359
| +0.5% | +$1.92M |
|
11
Magna International
MGA
$17.9B
| $429M | 1% |
7,828,603
+2,438,726
| +45% | +$132M |
|
12
Intuit
INTU
$81.1B
| $426M | 0.99% |
1,627,460
+82,266
| +5% | +$21.5M |
|
|
13
Micron Technology
MU
$1.04T
| $397M | 0.92% |
7,385,681
+3,864,831
| +110% | +$185M |
|
14
Novartis
NVS
$295B
| $384M | 0.89% |
4,058,336
+824,906
| +26% | +$74M |
|
15
PayPal
PYPL
$49.5B
| $382M | 0.89% |
3,527,217
-988,166
| -22% | -$103M |
|
16
TSMC
TSM
$2.09T
| $377M | 0.88% |
6,480,764
-1,185,744
| -15% | -$62.9M |
|
17
Automatic Data Processing
ADP
$100B
| $368M | 0.86% |
2,159,478
-246,723
| -10% | -$40.9M |
|
18
Johnson & Johnson
JNJ
$635B
| $367M | 0.85% |
2,515,629
-238,661
| -9% | -$32.4M |
|
19
Prudential Financial
PRU
$41.7B
| $355M | 0.83% |
3,790,879
+1,185,669
| +46% | +$109M |
|
20
BHP
BHP
$213B
| $354M | 0.82% |
7,254,645
-17,643
| -0.2% | -$801K |
|
21
iShares MSCI South Korea ETF
EWY
$21.7B
| $351M | 0.82% |
5,647,028
+755,865
| +15% | +$44.8M |
|
22
Lam Research
LRCX
$382B
| $350M | 0.81% |
11,984,070
+3,569,000
| +42% | +$94.8M |
|
23
Adobe
ADBE
$89.5B
| $344M | 0.8% |
1,043,038
+36,729
| +4% | +$10.8M |
|
|
BBL
24
DELISTED
BHP Group Plc American Depositary Shares (Each representing two Ordinary Shares)
BBL
| $337M | 0.78% |
7,178,341
+59,304
| +0.8% | +$2.61M |
|
25
Stellantis
STLA
$16.5B
| $323M | 0.75% |
21,808,772
+8,803,329
| +68% | +$127M |
|
Similar funds
VGA
Arrowstreet Capital's Q4 2019 Portfolio in Review
As of Q4 2019, Arrowstreet Capital held 2,029 positions worth $43B, up 0.28% from $42.9B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Arrowstreet Capital withdrew a net $3.21B in Q4 2019, closing 331 positions and reducing 446 holdings. Its most notable exit was Celgene Corp, an estimated $505M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 19% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Arrowstreet Capital opened a new position in Edwards Lifesciences worth $127M.
- Arrowstreet Capital's largest Q4 2019 buy was Edwards Lifesciences: 1,637,208 shares worth $127M.
- Arrowstreet Capital added most to Intel in Q4 2019, an estimated $285M increase.
- Arrowstreet Capital's biggest Q4 2019 reduction was Union Pacific, cutting an estimated $329M.
- Arrowstreet Capital fully exited Celgene Corp in Q4 2019, selling an estimated $505M.
- Arrowstreet Capital's ten largest holdings make up 19% of its $43B portfolio in Q4 2019.
- Arrowstreet Capital opened 505 new positions and closed 331 in Q4 2019.
- Arrowstreet Capital's portfolio value rose 0.28% quarter-over-quarter to $43B.
Based on Arrowstreet Capital's 13F filing for Q4 2019, filed 13 Feb 2020.